

การศึกษาความสมบูรณ์ และการได้รับวัคซีนตรงตามกรอบเวลา ก่อนและหลังการใช้งานสมุดวัคซีน สำหรับผู้รับบริการ ณ ศูนย์สร้างเสริมสุขภาพ โรงพยาบาลมหาวิทยาลัยบูรพา

สุรสิงห์ สมบัติ สุรนาวังวงศ์
คณะแพทยศาสตร์ มหาวิทยาลัยบูรพา ชลบุรี

ส่งบทความ: 7 ก.พ. 2565
แก้ไขบทความ: 5 พ.ค. 2565
ตีพิมพ์บทความ: 20 พ.ค. 2565

บทคัดย่อ

วัตถุประสงค์การวิจัย: เพื่อศึกษาความสมบูรณ์ และการได้รับวัคซีนตรงตามกรอบเวลา ก่อนและหลังการใช้งานสมุดวัคซีนสำหรับผู้รับบริการที่ศูนย์สร้างเสริมสุขภาพ โรงพยาบาลมหาวิทยาลัยบูรพา

วิธีดำเนินการวิจัย: การศึกษาในครั้งนี้เป็นการศึกษาแบบย้อนกลับ เป็นการวิเคราะห์ข้อมูล การได้รับวัคซีนชนิด หลายเข็ม ของผู้ที่มารับบริการ ณ ศูนย์สร้างเสริมสุขภาพ โรงพยาบาลมหาวิทยาลัยบูรพา ได้นำเครื่องมือสมมติการบันทึกการได้รับวัคซีนส่วนบุคคล มาใช้ในการบันทึกการรับวัคซีนของผู้ที่มารับบริการ ซึ่งในการวิเคราะห์ข้อมูลได้เปรียบเทียบความแตกต่างของความสมบูรณ์ และการได้รับวัคซีนตรงตามกรอบเวลา ระหว่างกลุ่มที่ยังไม่ได้ใช้สมุดวัคซีนและกลุ่มที่มีการใช้สมุดวัคซีน โดยใช้การวิเคราะห์การถดถอยโลจิสติก ในการวิเคราะห์ความสัมพันธ์ของตัวแปร ที่ศึกษาคือความสมบูรณ์และการตรงตามกรอบเวลาของการได้รับวัคซีนระหว่างที่ไม่ได้ใช้สมุดบันทึกการรับวัคซีนส่วนบุคคลและกลุ่มที่ได้ใช้สมุดบันทึกการรับวัคซีนส่วนบุคคล

ผลการวิจัย: จากการศึกษาพบว่า กลุ่มที่ใช้สมุดวัคซีนมีอัตราการสมบูรณ์ และการตรงตามกรอบเวลาในการได้รับวัคซีนสูงกว่าก่อนการใช้สมุดวัคซีนอย่างมีนัยสำคัญทางสถิติ (p -value < 0.001) และเมื่อวิเคราะห์คุณลักษณะของประชากรยังพบว่ากลุ่มอายุที่มากกว่า 35 ปีมีความสัมพันธ์กับการสมบูรณ์ และการตรงตามกรอบเวลาในการได้รับวัคซีนอย่างมีนัยสำคัญทางสถิติ (p -value < 0.001)

สรุปผล: ความสมบูรณ์และการตรงตามกรอบเวลาของการได้รับวัคซีนที่เพิ่มขึ้นจากกระบวนการใช้สมุดบันทึกการรับวัคซีนส่วนบุคคล เนื่องจากใช้สมุดบันทึกการรับวัคซีนส่วนบุคคล สามารถปรับให้มีความเหมาะสมและตอบสนองความต้องการของข้อมูลประชากรของผู้บริการวัคซีน เพื่อให้เกิดความสมบูรณ์และการได้รับวัคซีนครบถ้วนตามมาตรฐาน

คำสำคัญ: ความสมบูรณ์ของการรับวัคซีน, ความตรงตามกรอบเวลากำหนดการรับวัคซีน, สมุดวัคซีน

ติดต่อบทความ

สุรสิงห์ สมบัติ สุรนาวังวงศ์, คณะแพทยศาสตร์ มหาวิทยาลัยบูรพา ชลบุรี
E-mail: Shakti.kriangsak@gmail.com

Implementation of personal vaccination record (PVR) to increase completeness and adherence of multi-dose adult vaccination: a retrospective study at the wellness center, Burapha University Hospital

Surasingha Sombat Suranartwatchawong
Faculty of Medicine, Burapha University, Chonburi

Submitted: 7 Feb 2022
Revised: 5 May 2022
Published: 20 May 2022

Background: Failure to complete multi-dose vaccination was profound in adults globally. The reminder and recall system were proposed to improve immunization rates. We implemented the personal vaccination record (PVR) for adult vaccine services at the wellness center, Burapha University Hospital and measured completion and adherence rate before and after implementation.

Methods: This retrospective study analyzed multi-dose vaccine recipient data at the wellness center, Burapha University Hospital during 2019-2020. The PVR was implemented from 2020 onward; recipients who initiated the vaccine before and after PVR were categorized as pre-PVR and post-PVR groups, respectively. The outcomes were completeness and adherence rate. Completeness is defined as the completion of the standard vaccine series: 3 doses for Hepatitis B (HBV) and Human papilloma virus (HPV) vaccines, 2 doses for Measles-mumps-rubella vaccine (MMR) and varicella vaccine (VAR). Adherence is defined as receiving the vaccines per recommended schedule or within a window period of an additional one week.

Results: The completion and adherence rate were significantly higher in the post-PVR vs. pre-PVR group. The completion and adherence rate of post-PVR group were significantly higher than pre-PVR group (88.6% vs. 60.1% and 85.9% vs. 55.2% respectively). When adjusted for demographic data, PVR implementation and aged >35 years old were significantly associated with the completeness and adherence of multi-dose vaccine series.

Conclusions: Vaccination series completeness and adherence were higher after the PVR was implemented, especially among older adults. The PVR, or other forms of reminder systems, should be incorporated into every adult vaccination service to promote complete receiving recommended vaccines and immunization.

Keywords: Vaccine series completion, adherence, schedule, vaccine

Contact:

Surasingha Sombat Suranartwatchawong, Faculty of Medicine, Burapha University, Chonburi
E-mail: Shakti.kriangsak@gmail.com

Introduction

After the pandemic of Coronavirus disease 2019 (COVID-19), health and well-being have become the priority of people worldwide. The traditional concept of “Prevention is better than cure.” was reintroduced. Vaccination is among the most effective measures against diseases and transmission. The pandemic has increased vaccination awareness and acceptance among the adult population. A study in the United Kingdom found an increasing intention for influenza 2020-2021 vaccination for eligible adults, boosted after the COVID-19 pandemic.^[1] In order to ensure a protective immune response and maximize vaccine cost-effectiveness, the vaccination process, including multi-dose vaccine schedules, should adhere to the manufacturer’s recommendation.

However, incomplete multi-dose vaccination was reported as a problem globally. In a review of vaccine series completion among adolescent- including human papillomavirus vaccine (HPV), hepatitis A (HAV), hepatitis B (HBV), and varicella vaccines (VAR)- found completion rates ranged from 27% to over 90%.^[2] The rate of completed vaccination was particularly lower in adolescent and young adult.^[3] Studies from the United States found that only one-third of

adults completely received HAV and HBV vaccination.^[4] Suboptimal adherence and series completion rate (23-35%) was also described among adults in the United Kingdom receiving hepatitis vaccines.^[5] The data among adult vaccine recipients were limited in Thailand.

Factors influencing successful vaccination can be considered upon many concepts. The World Health Organization (WHO) vaccine hesitancy model is composed of confidence, complacency, and convenience.^[6] Confidence refers to a lack of trust in the effectiveness and safety of vaccines, health care personnel, or related system. Complacency refers to a low perceived risk of vaccine-preventable diseases and the fact that vaccines are important. Convenience refers to the degree of discomfort, inconvenient in time and place, of vaccine delivery system including the complexity of multiple series of vaccines. In terms of multi-dose vaccination, the vaccine reminder/recall system, as part of the convenience, has been shown to improve coverage compared to the control group.^[7]

In a qualitative study among US adolescents who missed the final dose of the HPV vaccine, more than one-third claimed that they did not know and/or forgot to obtain further

doses.^[8] Not only for the vaccine recipients, but a good reminder system will also assist health care personnel to provide vaccines per the most appropriate schedule. As the wellness center, Burapha University Hospital thrives to be an excellent center for health preventive medicine, the personal vaccination record (PVR) was implemented in January 2020. Regarding a scarce of local data, we conducted a retrospective study comparing the completion and adherence rate of multi-dose vaccine recipients in the wellness center before and after the implementation of personal vaccination records (PVR).

Methods and Materials

Research setting:

This research utilized retrospective vaccination data from the wellness center, Burapha University Hospital in Chonburi, Thailand. The center has extended the service toward preventive medicine, this includes the provision of vaccine to adult aged >18 years. There were 600 - 675 vaccine recipients during 2019-2020. This number has been increasing. The nurse who provides the vaccination will record related data as a routine process. The data include the vaccinees' demographics, type, date, and route of vaccinations. Multi-dose vaccinations are accounted for half of the overall vaccine services. These

included HBV, HPV, measles-mumps-rubella (MMR) and, Varicella (VAR) vaccines. The PVR was implemented as a research and development project funded by the Faculty of Medicine, Burapha University. Vaccination schedule for HBV in this research is three muscular injections, the second and third doses are administered at 1 and 6 months, after the first dose respectively HPV vaccination schedule also consists of three muscular injections, the second and third doses are administered at 2 and 6 months, respectively after the first dose. For subcutaneous MMR and VAR vaccination schedule, the second dose is administered at 4 weeks after the first dose.

Before the PVR, the appointment of a multi-dose vaccine schedule was administered by pharmacists or nursing personnel, depending on the type of vaccine. The appointment date was printed and given to the recipient as a single piece of paper. Sometimes the appointment card was uninformed or lost. According to the recorded data, almost half of the recipients were unsuccessful to receive vaccines within appropriate schedule and 40% did not complete the vaccination during pre-PVR. The PVR was developed by multidisciplinary health care personnel involving in adult vaccine services The

format (Figure 1) was modified from the renowned national vaccination center and World Health Organization guidelines.^[9] The nurse will fill in the vaccinee's demographic on the front page; vaccine-related detail along with the date of the next vaccination

schedule are filled in and discussed with the recipient. There are contents to increase awareness of vaccine schedule and side effects on the back page. The PVR was implemented from January 2020 onward.

3 Vaccination Record

Vaccine or prophylaxis	Date	Reaction and batch no. of vaccine or prophylaxis	Next booster	Official stamp of administering center
1.				
2.				
3.				
4.				
5.				

4

9 คำแนะนำฉีดวัคซีน

10 Travel and Adult vaccination

Vaccine	Schedule	Remarks
MMR2	1 dose at 18 months, 2 doses at 24 months and 5 years	
MMR3	1 dose at 4 years, 2 doses at 5 years and 13 years	
MMR4	1 dose at 13 years, 2 doses at 18 years and 25 years	
MMR5	1 dose at 18 years, 2 doses at 23 years and 28 years	
MMR6	1 dose at 23 years, 2 doses at 28 years and 33 years	
MMR7	1 dose at 28 years, 2 doses at 33 years and 38 years	
MMR8	1 dose at 33 years, 2 doses at 38 years and 43 years	
MMR9	1 dose at 38 years, 2 doses at 43 years and 48 years	
MMR10	1 dose at 43 years, 2 doses at 48 years and 53 years	
MMR11	1 dose at 48 years, 2 doses at 53 years and 58 years	
MMR12	1 dose at 53 years, 2 doses at 58 years and 63 years	
MMR13	1 dose at 58 years, 2 doses at 63 years and 68 years	
MMR14	1 dose at 63 years, 2 doses at 68 years and 73 years	
MMR15	1 dose at 68 years, 2 doses at 73 years and 78 years	
MMR16	1 dose at 73 years, 2 doses at 78 years and 83 years	
MMR17	1 dose at 78 years, 2 doses at 83 years and 88 years	
MMR18	1 dose at 83 years, 2 doses at 88 years and 93 years	
MMR19	1 dose at 88 years, 2 doses at 93 years and 98 years	
MMR20	1 dose at 93 years, 2 doses at 98 years and 103 years	
MMR21	1 dose at 98 years, 2 doses at 103 years and 108 years	
MMR22	1 dose at 103 years, 2 doses at 108 years and 113 years	
MMR23	1 dose at 108 years, 2 doses at 113 years and 118 years	
MMR24	1 dose at 113 years, 2 doses at 118 years and 123 years	
MMR25	1 dose at 118 years, 2 doses at 123 years and 128 years	
MMR26	1 dose at 123 years, 2 doses at 128 years and 133 years	
MMR27	1 dose at 128 years, 2 doses at 133 years and 138 years	
MMR28	1 dose at 133 years, 2 doses at 138 years and 143 years	
MMR29	1 dose at 138 years, 2 doses at 143 years and 148 years	
MMR30	1 dose at 143 years, 2 doses at 148 years and 153 years	
MMR31	1 dose at 148 years, 2 doses at 153 years and 158 years	
MMR32	1 dose at 153 years, 2 doses at 158 years and 163 years	
MMR33	1 dose at 158 years, 2 doses at 163 years and 168 years	
MMR34	1 dose at 163 years, 2 doses at 168 years and 173 years	
MMR35	1 dose at 168 years, 2 doses at 173 years and 178 years	
MMR36	1 dose at 173 years, 2 doses at 178 years and 183 years	
MMR37	1 dose at 178 years, 2 doses at 183 years and 188 years	
MMR38	1 dose at 183 years, 2 doses at 188 years and 193 years	
MMR39	1 dose at 188 years, 2 doses at 193 years and 198 years	
MMR40	1 dose at 193 years, 2 doses at 198 years and 203 years	
MMR41	1 dose at 198 years, 2 doses at 203 years and 208 years	
MMR42	1 dose at 203 years, 2 doses at 208 years and 213 years	
MMR43	1 dose at 208 years, 2 doses at 213 years and 218 years	
MMR44	1 dose at 213 years, 2 doses at 218 years and 223 years	
MMR45	1 dose at 218 years, 2 doses at 223 years and 228 years	
MMR46	1 dose at 223 years, 2 doses at 228 years and 233 years	
MMR47	1 dose at 228 years, 2 doses at 233 years and 238 years	
MMR48	1 dose at 233 years, 2 doses at 238 years and 243 years	
MMR49	1 dose at 238 years, 2 doses at 243 years and 248 years	
MMR50	1 dose at 243 years, 2 doses at 248 years and 253 years	
MMR51	1 dose at 248 years, 2 doses at 253 years and 258 years	
MMR52	1 dose at 253 years, 2 doses at 258 years and 263 years	
MMR53	1 dose at 258 years, 2 doses at 263 years and 268 years	
MMR54	1 dose at 263 years, 2 doses at 268 years and 273 years	
MMR55	1 dose at 268 years, 2 doses at 273 years and 278 years	
MMR56	1 dose at 273 years, 2 doses at 278 years and 283 years	
MMR57	1 dose at 278 years, 2 doses at 283 years and 288 years	
MMR58	1 dose at 283 years, 2 doses at 288 years and 293 years	
MMR59	1 dose at 288 years, 2 doses at 293 years and 298 years	
MMR60	1 dose at 293 years, 2 doses at 298 years and 303 years	
MMR61	1 dose at 298 years, 2 doses at 303 years and 308 years	
MMR62	1 dose at 303 years, 2 doses at 308 years and 313 years	
MMR63	1 dose at 308 years, 2 doses at 313 years and 318 years	
MMR64	1 dose at 313 years, 2 doses at 318 years and 323 years	
MMR65	1 dose at 318 years, 2 doses at 323 years and 328 years	
MMR66	1 dose at 323 years, 2 doses at 328 years and 333 years	
MMR67	1 dose at 328 years, 2 doses at 333 years and 338 years	
MMR68	1 dose at 333 years, 2 doses at 338 years and 343 years	
MMR69	1 dose at 338 years, 2 doses at 343 years and 348 years	
MMR70	1 dose at 343 years, 2 doses at 348 years and 353 years	
MMR71	1 dose at 348 years, 2 doses at 353 years and 358 years	
MMR72	1 dose at 353 years, 2 doses at 358 years and 363 years	
MMR73	1 dose at 358 years, 2 doses at 363 years and 368 years	
MMR74	1 dose at 363 years, 2 doses at 368 years and 373 years	
MMR75	1 dose at 368 years, 2 doses at 373 years and 378 years	
MMR76	1 dose at 373 years, 2 doses at 378 years and 383 years	
MMR77	1 dose at 378 years, 2 doses at 383 years and 388 years	
MMR78	1 dose at 383 years, 2 doses at 388 years and 393 years	
MMR79	1 dose at 388 years, 2 doses at 393 years and 398 years	
MMR80	1 dose at 393 years, 2 doses at 398 years and 403 years	
MMR81	1 dose at 398 years, 2 doses at 403 years and 408 years	
MMR82	1 dose at 403 years, 2 doses at 408 years and 413 years	
MMR83	1 dose at 408 years, 2 doses at 413 years and 418 years	
MMR84	1 dose at 413 years, 2 doses at 418 years and 423 years	
MMR85	1 dose at 418 years, 2 doses at 423 years and 428 years	
MMR86	1 dose at 423 years, 2 doses at 428 years and 433 years	
MMR87	1 dose at 428 years, 2 doses at 433 years and 438 years	
MMR88	1 dose at 433 years, 2 doses at 438 years and 443 years	
MMR89	1 dose at 438 years, 2 doses at 443 years and 448 years	
MMR90	1 dose at 443 years, 2 doses at 448 years and 453 years	
MMR91	1 dose at 448 years, 2 doses at 453 years and 458 years	
MMR92	1 dose at 453 years, 2 doses at 458 years and 463 years	
MMR93	1 dose at 458 years, 2 doses at 463 years and 468 years	
MMR94	1 dose at 463 years, 2 doses at 468 years and 473 years	
MMR95	1 dose at 468 years, 2 doses at 473 years and 478 years	
MMR96	1 dose at 473 years, 2 doses at 478 years and 483 years	
MMR97	1 dose at 478 years, 2 doses at 483 years and 488 years	
MMR98	1 dose at 483 years, 2 doses at 488 years and 493 years	
MMR99	1 dose at 488 years, 2 doses at 493 years and 498 years	
MMR100	1 dose at 493 years, 2 doses at 498 years and 503 years	

Figure 1 Format of Personal vaccination record (PVR) at the wellness center, Burapha University Hospital

Study population

Records of vaccine recipients aged 18 years or older who had received multi-dose vaccines (HBV, HPV MMR, Varicella) 1 year before and after PVR were retrieved. We excluded data of vaccine recipients who initiated multiple vaccine series at the same visit and booster doses or accelerated vaccine schedules were also excluded. We only collected the first type of vaccines if the recipient received more than one type of multi-dose vaccines during the study period.

Outcome measures

The primary study outcomes were (1) completion of the standard course of the multi-dose vaccines

(defined in this study as HBV 3 doses, HPV 3 doses, MMR 2 doses, and VAR vaccine 2 doses) and (2) the adherence to the recommended timing of the vaccines as in Thai vaccination guideline for adult (Table 1). Statistic calculation was performed with the proportions of adults who completed two and three doses and the proportions who adhered to the recommended schedule or within one additional week after the appointment date. The comparison was made between recipients who came 1 year before PVR implementation (pre-PVR group) and 1 year after PVR (post-PVR group)

Table 1 Recommended adult administration schedules for Hepatitis B, HPV (Human Papilloma Virus), Measles-mumps-rubella, Varicella vaccine at the Wellness Center Burapha University Hospital

Vaccine	Recommended schedule			injection technique
	Dose 1	Dose 2	Dose 3	
Hepatitis B	0	1 month	6 months	muscular injection
Human Papilloma Virus	0	2 months	6 months	muscular injection
Measles-mumps-rubella	0	1 month	N/A	subcutaneous injection
Varicella	0	1 month	N/A	subcutaneous injection

Statistical analysis

Demographics of vaccine recipients, the proportion of vaccine series completion, and adherence were summarized descriptively, then categorized as pre-PVR and post-PVR groups. Categorical covariates were described as a number and percentage; continuous covariates were described as mean and standard deviation (SD). Comparisons between categorical and continuous variables in pre-and post-PVR groups were made using Chi-square and T-test respectively. All p-values reported are two-sided, and statistical significance was defined as $p < 0.05$. Logistic regression analysis was used to determine an odds ratio (OR) and 95 % confidence intervals (CI) for factors associated with vaccine series completion and adherence. Multivariable models were developed adjusting for demographic and

covariates with $p < 0.1$ in univariate models. The study procedure was approved by the Burapha University Institutional Review Board.

Results

The data of 628 adults initiating multi-dose vaccination during 1 year before and after PVR were screened for eligibility. Forty-seven vaccinees were excluded because receiving more than one multi-dose vaccination in the same visit and ten vaccinees were excluded because of receiving only a booster dose. Therefore, a total of 571 vaccine recipients (308 and 263 from pre-PVR and post-PVR groups, respectively) were included in this analysis. Most vaccine recipients were Thai people with a mean age of 33 (SD=13.27) years; more than half (66%) of them were female (Table 2)

Table 2 Characteristics of adult (N=571), classified by vaccine series initiation before (pre-PVR) and after (post-PVR) implementation of personal vaccine record

	Pre-PVR (n = 308) (%)	Post-PVR (n = 263) (%)	p-value
Gender			
Female	217 (70.5)	161 (61.2)	0.020*
Male	91 (29.5)	102(38.8)	
Mean age (years) ± SD	34.93±14.22	31.67±13.27	0.005*
Nationality			
Thais	303 (98.4)	259 (98.5)	0.992
Foreigners	5 (1.6)	4 (1.5)	
Total vaccination received			
HBV	217 (70.5)	196 (74.5)	< 0.001*
HPV	6 (1.9)	20 (7.6)	
MMR	43 (14.0)	44 (16.7)	
VAR	42 (13.6)	3 (1.1)	
Vaccines Series completion	185 (60.1)	233 (88.6)	< 0.001*
Vaccines Series adherence	170 (55.2)	226 (85.9)	< 0.001*

* Significant with *p*-value <0.05; Human Papillomavirus Vaccine: HPV, Measles-Mumps-Rubella Vaccine: MMR, Hepatitis B Vaccine: HBV, Varicella Vaccines: VAR, Personal vaccine record : PVR

Vaccine series completion and adherence rate

Seventy-seven percent of total vaccination data were 3 dose series (HBV 72 % and HPV 5%); two-dose series consisted of MMR 15% and varicella vaccine 8%. The three-dose series were accounted for more than 80% of the recipient data in the post-PVR period. The completion rate of vaccine series was significantly higher among post-PVR compared to pre-PVR (88.6% vs. 60.1 % respectively), *p* < 0.001. A higher proportion was also observed for adherence rate (85.9% vs. 55.2 % respectively), *p* < 0.001.

In univariate analysis, age>35 years and receiving vaccine post-PVR were significantly associated with vaccine series completion. When adjusted for demographics, these two factors (aOR 2.38 (95 % CI 1.52–3.75), *p* <0.001) and (aOR 6.52 (95 % CI 4.06–10.47), *p* <0.001), respectively, were independently associated with vaccine series completion (Table 3). They were also associated with adherence to vaccine series (aOR 2.65 (95 % CI 1.70–4.12), *p* <0.001) and (aOR 5.95 (95 % CI 3.86–9.17), *p* <0.001), respectively (Table 4). Moreover, 2-doses vaccine series were significantly associated with adherence in the univariate model.

Table 3 Univariate and Multivariate association of vaccines series completion among adult vaccine recipient at the Wellness Center Burapha University Hospital during 2019-2020 (N=571)

Factors *	Univariate		Multivariate	
	Crude OR (95%CI)	p-value	Adjusted OR (95%CI)	p-value
Gender				
Female	1.03 (0.70-1.52)	0.887	0.88 (0.57-1.35)	0.554
Male	1 (ref)			
Age Group				
>35 years	1.64 (1.09-2.45)	0.017*	2.38 (1.52-3.75)	< 0.001*
< 35 years	1 (ref)			
Nationality				
Thai	2.97 (0.37-23.91)	0.307	3.48(0.40-30.17)	0.258
Foreign	1 (ref)			
Post-PVR	5.16 (3.31-8.14)	< 0.001*	6.52 (4.06-10.47)	< 0.001*
Pre-PVR	1(ref)			
Type of immunization				
- 2 doses	1.41 (0.73-2.70)	0.304	0.54 (0.27-1.10)	0.091
- 3 doses	1 (ref)			

* Significant with p-value <0.05

Table 4 Univariate and Multivariate association of adherence among adult vaccine recipient at the Wellness Center Burapha University Hospital during 2019-2020 (N=571)

Factors *	Univariate		Multivariate	
	OR (95%CI)	P value	aOR (95%CI)	P value
Gender				
Female	1.04 (0.72-1.52)	0.825	0.93 (0.61-1.41)	0.733
Male	1 (ref)			
Age Group				
>35 years	1.98 (1.34-2.94)	0.001*	2.65 (1.70-4.12)	< 0.001*
< 35 years	1 (ref)			
Nationality				
Thai	0.28 (0.34-2.25)	0.230	0.19 (0.02-1.64)	0.130
Foreign	1 (ref)			
Post-PVR	4.96 (3.28-7.50)	< 0.001*	5.95 (3.86-9.17)	< 0.001*
Pre-PVR	1 (ref)			
Type of immunization				
- 2 doses	2.84 (1.53-5.25)	0.001*	1.14 (0.57-2.25)	0.714
- 3 doses	1 (ref)			

* Significant with p-value <0.05

Discussion

In this study, we described vaccine series completion and adherence among multi-dose vaccine recipients at the wellness center, Burapha University hospital. We demonstrated a higher proportion of vaccine series completion 88.6% and an adherence rate of 86% after the PVR was implemented. Referring to the WHO vaccine hesitancy model, the vaccine record functions as a reminder system to reduce the complexity of multi-dose vaccine series, thus promoting convenience. This has been demonstrated successfully in childhood vaccination programs worldwide.^[10] Although, some dedicated adult vaccination centers are providing the vaccine record, i.e., travel clinics, the majority of adult vaccine clinics did not. We call for the wide-scale use of the adult vaccination record.

Most of the vaccine recipients in our study were Thai. It should be kept in mind that the rate of vaccine acceptance can be varied among countries and settings. Considering the WHO vaccine hesitancy model, vaccine confidence and complacency are significantly higher in Thailand comparing to the global data.^[11] Thai people are likely to follow the advice of their trusted health care personnel. Local data showed that the influenza

vaccine acceptance increases if the vaccine was recommended by the doctor.^[12] Our study found higher vaccine completion and adherence rate among adults aged more than 35 years. Older adults might have more chances to visit the doctor. Therefore, they are more likely to concern about the vaccination schedule.

The reminder system can be varied in format. It should be made appropriate for the demographics of vaccine recipients.^[13] Even with the vaccine record, we found lower vaccine series completion and adherence rate among adults aged lower than 35 years old. The vaccine record as a paperback may still be lost or forgotten. As smartphone ownership is growing rapidly in terms of number and necessity, the reminder system might be adjusted toward this trend. Electronic vaccination record or text reminder on the smartphone has been shown to increased vaccine adherence as well.^[14] This format might be more appropriate among younger adults and adolescents. However, personal data protection should always be considered and consented.

There are some limitations to our study. First, during the situation of the COVID-19 pandemics, there might be other factors influencing vaccine series completion and adherence such as increasing vaccine demand, vaccine

supply shortage, and travel restriction which inhibited the hospital visit. The findings must be interpreted cautiously in regard to the situation. Second, this study used a retrospective study design, which unable to direct comparison between pre-PVR and post-PVR groups. Lastly, the study was conducted solely at the wellness center, Burapha University Hospital, the finding could be limited to generalized to every vaccination center. The reminder system should be adjusted by the demographics of vaccine recipients.

In summary, vaccine series completion and adherence were associated with the implementation of

PVR in adult vaccine recipients at the wellness center, Burapha University Hospital. The completion and adherence were also associated with an adult older than 35 years. The vaccine record is one form of the reminder system which format should be individualized to settings and recipient demographics. The reminder system is not only convenient for the recipient but also for health care personnel who can review and give the most appropriate vaccine per type and schedule. We strongly advocate for the vaccine reminder system for every adult vaccination center, so that protective immunity and vaccine cost-effectiveness could be achieved.

Reference

1. Bachtiger P, Adamson A, Chow JJ, Sisodia R, Quint JK, Peters NS. The Impact of the COVID-19 Pandemic on the Uptake of Influenza Vaccine: UK-Wide Observational Study. *JMIR Public Health Surveill.* 2021;7(4):e26734. doi: 10.2196/26734.
2. Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, Donahue JG, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. *Am J Public Health.* 2009;99(Suppl2):S389-97. doi: 10.2105/AJPH.2008.151332
3. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. *BMC Public Health.* 2016;16:172. doi: 10.1186/s12889-016-2845-z.
4. Trantham L, Kurosky SK, Zhang D, Johnson KD. Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. *Vaccine.* 2018;36(35):5333-9. doi: 10.1016/j.vaccine.2018.05.111.

5. Johnson KD, Lu X, Zhang D. Adherence to hepatitis A and hepatitis B multi-dose vaccination schedules among adults in the United Kingdom: a retrospective cohort study. BMC Public Health. 2019;19(1):404. doi: 10.1186/s12889-019-6693-5.
6. World Health Organization. Report of the sage working group on vaccine hesitancy [Internet]. USA: World Health Organization; 2014. Available from: <https://www.thecompassforsbc.org/sbcc-tools/report-sage-working-group-vaccine-hesitancy>
7. World Health Organization. Strengthening health security by implementing the International Health Regulations [Internet]. America: World Health Organization; 2005. Available from: https://www.who.int/ihr/ports_airports/icvp_note/en/
8. Dorell CG, Stokley S, Yankey D, Markowitz LE. Compliance with recommended dosing intervals for HPV vaccination among females, 13–17 years, National Immunization Survey-Teen, 2008–2009. Vaccine. 2012;30(3):503-5. doi: 10.1016/j.vaccine.2011.11.042.
9. Infectious Disease Association of Thailand. Recommended Adult and Elderly Immunization Schedule [Internet]. Bangkok: Infectious Disease Association of Thailand; 2018. Available from: <https://www.idthai.org/Contents/Views/?d=ZTue!17!4!!390!BiuJHPad.%20Jennifer>.
10. Orenstein WA. Pediatricians called on to do their part to support adult immunization. AAP News. 2014;35(4):8.
11. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898-908. doi: 10.1016/S0140-6736(20)31558-0.
12. Phrommintikul A, Wongcharoen W, Kuanprasert S, Prasertwitayakij N, Kanjanavanit R, Gunaparn S, et al. Safety and tolerability of intradermal influenza vaccination in patients with cardiovascular disease. J Geriatr Cardiol. 2014;11(2):131-5. doi: 10.3969/j.issn.1671-5411.2014.02.007.
13. Abahussin AA, Albarrak AI. Vaccination adherence: Review and proposed model. J Infect Public Health. 2016;9(6):781-9. doi: 10.1016/j.jiph.2016.09.006.
14. Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjiei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1(1):CD003941. doi: 10.1002/14651858.CD003941.pub3.